source
- Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trialLatigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain treatment Journavx. Next, Latigo h…Endpoints · 17m ago↗ source
- Apnimed raises $192M IPO for potential 2027 sleep apnea drug launchIn the city that never sleeps, a sleep apnea drug developer has secured a $192 million IPO after more than three years of eyeing a Nasdaq debut. Apnimed is slated to begin ...Endpoints · 23m ago↗ source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…